Shanghai-based Harbour BioMed’s acquisition of a stake in US-based Spruce Biosciences is the latest example of China’s novel drug developers progressing from one-time licensing deals into long-lasting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results